Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017

Details for Mechanism ID: 18190
Country/Region: Caribbean Region
Year: 2017
Main Partner: Ministry of Health - Guyana
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $362,296 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $50,000
Care: Pediatric Care and Support (PDCS) $20,000
Laboratory Infrastructure (HLAB) $65,000
Strategic Information (HVSI) $80,000
Treatment: Adult Treatment (HTXS) $107,296
Treatment: Pediatric Treatment (PDTX) $40,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
TX_CURR Aggregated Age/Sex: <15 Female 2018 19
TX_CURR Aggregated Age/Sex: <15 Male 2018 19
TX_CURR Aggregated Age/Sex: 15+ Female 2018 851
TX_CURR Aggregated Age/Sex: 15+ Male 2018 1,002
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 1,891
TX_CURR Sum of Aggregated Age/Sex <15 2018 38
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 1,853
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 1,891
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 4
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 4
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 192
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 226
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 426
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 426
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 1,702
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 1,362
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 14
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 14
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 612
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 722
TX_PVLS Numerator: Indication: Routine 2018 1,362
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 17
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 17
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 766
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 902
TX_PVLS_den Denominator: Indication: Routine 2018 1,702
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 3
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 3
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 134
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 157
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 297
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 349
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 158
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 185
Cross Cutting Budget Categories and Known Amounts Total: $280,000
Key Populations: MSM and TG $140,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $140,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs